Quick Answer
Prelude Therapeutics Inc reported R&D Expense of $94.30 million for fiscal year 2025.
Prelude Therapeutics Inc R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $94.30M | -20.1% |
| 2024 | $118.00M | +14.1% |
| 2023 | $103.39M | +11.3% |
| 2022 | $92.89M | +7.0% |
| 2021 | $86.78M | +80.1% |
| 2020 | $48.18M | +98.4% |
| 2019 | $24.28M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $21.71M | -26.3% | -15.8% |
| June 30, 2025 | $25.78M | -12.6% | -10.5% |
| March 31, 2025 | $28.82M | +5.1% | -2.2% |
| September 30, 2024 | $29.46M | +12.2% | -0.2% |
| June 30, 2024 | $29.51M | +18.2% | +7.7% |
| March 31, 2024 | $27.41M | +25.5% | +4.4% |
| September 30, 2023 | $26.26M | +14.7% | +5.2% |
| June 30, 2023 | $24.97M | +17.2% | +14.3% |
- Prelude Therapeutics Inc showed a decrease of -20.1% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Prelude Therapeutics Inc’s r&d expense has grown by 288.4% (from $24.28 million to $94.30 million).
- The most recent figure is from Prelude Therapeutics Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: